New cocktail of drugs takes on Hard-to-Treat myeloma

NCT ID NCT05372354

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing several new drug combinations, including an experimental drug called CC-92480, in people with multiple myeloma that has come back or stopped responding to treatment. The main goals are to check safety and find the right doses. About 260 participants will be enrolled across multiple sites. If the combinations show promise, they could offer new options for controlling this blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-92480 (BMS-986348) combined with other drugs (tazemetostat, BMS-986158, trametinib, dexamethasone)
What this could lead to: If successful, this could point toward new treatment options for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1b/2a) with a small number of participants, so the results may not lead to a proven treatment. The drug combinations may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Alberta Health Services AHS - Foothills Medical Centre FMC
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Churchill Hospital
RECRUITING

Oxford, Oxfordshire, OX3 7LE, United Kingdom
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Marques de Valdecilla
RECRUITING

Santander, 39008, Spain
ICO - Hospital Germans Trias i Pujol
RECRUITING

Barcelona, 08026, Spain
John Theurer Cancer Center at Hackensack UMC
RECRUITING

Hackensack, New Jersey, 07601, United States
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States
Local Institution - 0001
WITHDRAWN

Leicester, Leicestershire, LE1 5WW, United Kingdom
Local Institution - 0014
WITHDRAWN

Liverpool, Merseyside, L7 8YA, United Kingdom
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
NIHR UCLH Clinical Research Facility
RECRUITING

London, W1T 7HA, United Kingdom
Oslo University Hospital
RECRUITING

Oslo, Outside US and Canada, 0450, Norway
The Christie NHS Foundation Trust
RECRUITING

Manchester, Greater Manchester, M20 4BX, United Kingdom
UAB Comprehensive Cancer Center
RECRUITING

Birmingham, Alabama, 35249, United States
University Health Network UHN - Princess Margaret Hospital PMH
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
University of Alberta - Cross Cancer Institute
RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.